Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22500
Title: FGF13 promotes metastasis of triple-negative breast cancer.
Authors: Johnstone, Cameron N;Pattison, Andrew D;Harrison, Paul F;Powell, David R;Lock, Peter;Ernst, Matthias;Anderson, Robin L;Beilharz, Traude H
Affiliation: LIMS Bioimaging Facility, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia
Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
Monash Bioinformatics Platform, Monash University, Clayton, Victoria, Australia
Cancer Research Division, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Issue Date: 19-Jan-2020
EDate: 2020-01-19
Citation: International journal of cancer 2020; online first: 19 January
Abstract: Triple-negative breast cancer (TNBC) represents 10-20% of all human ductal adenocarcinomas and has a poor prognosis relative to other subtypes, due to the high propensity to develop distant metastases. Hence, new molecular targets for therapeutic intervention are needed for TNBC. We recently conducted a rigorous phenotypic and genomic characterization of four isogenic populations of MDA-MB-231 human triple-negative breast cancer cells that possess a range of intrinsic spontaneous metastatic capacities in vivo, ranging from non-metastatic (MDA-MB-231_ATCC) to highly metastatic to lung, liver, spleen and spine (MDA-MB-231_HM). Gene expression profiling of primary tumours by RNA-Seq identified the fibroblast growth factor homologous factor, FGF13, as highly upregulated in aggressively metastatic MDA-MB-231_HM tumours. Clinically, higher FGF13 mRNA expression was associated with significantly worse relapse free survival in both luminal A and basal-like human breast cancers but was not associated with other clinical variables and was not upregulated in primary tumours relative to normal mammary gland. Stable FGF13 depletion restricted in vitro colony forming ability in MDA-MB-231_HM TNBC cells but not in oestrogen receptor (ER) positive MCF-7 or MDA-MB-361 cells. However, despite augmenting MDA-MB-231_HM cell migration and invasion in vitro, FGF13 suppression almost completely blocked the spontaneous metastasis of MDA-MB-231_HM orthotopic xenografts to both lung and liver while having negligible impact on primary tumour growth. Together, these data indicate that FGF13 may represent a therapeutic target for blocking metastatic outgrowth of certain TNBCs. Further evaluation of the roles of individual FGF13 protein isoforms in progression of the different subtypes of breast cancer is warranted. This article is protected by copyright. All rights reserved.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22500
DOI: 10.1002/ijc.32874
ORCID: 0000-0002-6464-8661
0000-0002-6399-1177
PubMed URL: 31957002
Type: Journal Article
Subjects: FGF13
metastasis
mouse model
triple-negative breast cancer
xenograft
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.